4Q PREVIEW: 'One Shire' pipeline news and ViroPharma update expected
This article was originally published in Scrip
Executive Summary
Though there have been bumps in the road for Shire recently – in the form of a Phase III failure for Vyvanse (lisdexamfetamine dimesylate) in major depressive disorder and the disposal of diabetic foot ulcer product Dermagraft for no money upfront – the firm has seen its stock continue on a steady upsurge.